Neonc Technologies Holdings Inc

NeOnc Technologies’ intranasal NEO100 shows 21% tumor response and 44% six‑month PFS in high‑grade glioma, fueling investor interest in CNS oncology.

NeOnc Technologies Holdings, Inc. is a biopharmaceutical company making significant advancements in brain cancer treatment through innovative drug delivery methods and targeted therapies.

NeOnc Technologies has secured a strategic partnership with Quazar Investment and joined the Russell Microcap Index, expanding its market presence and financial standing.